Search results
Results from the WOW.Com Content Network
Technetium (99m Tc) sestamibi (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined.
A bone scan or bone scintigraphy / s ɪ n ˈ t ɪ ɡ r ə f i / is a nuclear medicine imaging technique used to help diagnose and assess different bone diseases. These include cancer of the bone or metastasis, location of bone inflammation and fractures (that may not be visible in traditional X-ray images), and bone infection (osteomyelitis).
In order to obtain spatial information about the gamma-ray emissions from an imaging subject (e.g. a person's heart muscle cells which have absorbed an intravenous injected radioactive, usually thallium-201 or technetium-99m, medicinal imaging agent) a method of correlating the detected photons with their point of origin is required.
The nuclear stress test exhibits a sensitivity of 81% and a specificity ranging from 85 to 95%. [22] To arrive at the patient's post test likelihood of disease, the interpretation of the stress test result necessitates the integration of the patient's pretest likelihood with the test's sensitivity and specificity.
Nuclear medicine myocardial perfusion scan with thallium-201 for the rest images (bottom rows) and Tc-Sestamibi for the stress images (top rows). The nuclear medicine myocardial perfusion scan plays a pivotal role in the non-invasive evaluation of coronary artery disease. The study not only identifies patients with coronary artery disease; it ...
Myocardial perfusion imaging or scanning (also referred to as MPI or MPS) is a nuclear medicine procedure that illustrates the function of the heart muscle (). [1]It evaluates many heart conditions, such as coronary artery disease (CAD), [2] hypertrophic cardiomyopathy and heart wall motion abnormalities.
The test was first introduced in 1956, using iodine-131 diodrast. [25] [26] Later developments included iodine-131, and then iodine-123, labelled ortho-Iodohippuric acid (OIH, marketed as Hippuran). [27] [28] 99m Tc-MAG3 has replaced 131 I-OIH because of better quality imaging regardless of the level of kidney function, [29] and lower radiation ...
This nuclear medicine scan yields an accurate, inexpensive and easily reproducible means of measuring and monitoring the ejection and injection fractions of the ventricles, which are one of many of the important clinical metrics in assessing global heart performance. [citation needed]